MX369649B - Analogos de dioxolano de uridina para el tratamiento del cancer. - Google Patents

Analogos de dioxolano de uridina para el tratamiento del cancer.

Info

Publication number
MX369649B
MX369649B MX2017002328A MX2017002328A MX369649B MX 369649 B MX369649 B MX 369649B MX 2017002328 A MX2017002328 A MX 2017002328A MX 2017002328 A MX2017002328 A MX 2017002328A MX 369649 B MX369649 B MX 369649B
Authority
MX
Mexico
Prior art keywords
cancer
treatment
uridine
c6alkyl
dioxolane
Prior art date
Application number
MX2017002328A
Other languages
English (en)
Spanish (es)
Other versions
MX2017002328A (es
Inventor
BETHEL Richard
Eneroth Anders
Klasson Björn
Öberg Fredrik
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir Ab filed Critical Medivir Ab
Publication of MX2017002328A publication Critical patent/MX2017002328A/es
Publication of MX369649B publication Critical patent/MX369649B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2017002328A 2014-08-25 2015-08-24 Analogos de dioxolano de uridina para el tratamiento del cancer. MX369649B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1450983 2014-08-25
SE1550858 2015-06-22
PCT/EP2015/069370 WO2016030335A1 (en) 2014-08-25 2015-08-24 Dioxolane analogues of uridine for the treatment of cancer

Publications (2)

Publication Number Publication Date
MX2017002328A MX2017002328A (es) 2017-05-22
MX369649B true MX369649B (es) 2019-11-15

Family

ID=54014804

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002328A MX369649B (es) 2014-08-25 2015-08-24 Analogos de dioxolano de uridina para el tratamiento del cancer.

Country Status (24)

Country Link
US (7) US10144750B2 (en:Method)
EP (2) EP3572410B1 (en:Method)
JP (2) JP6663424B2 (en:Method)
KR (2) KR102398714B1 (en:Method)
CN (4) CN111269264A (en:Method)
AU (2) AU2015308988C1 (en:Method)
BR (1) BR112017003898B1 (en:Method)
CA (2) CA2956251C (en:Method)
CY (1) CY1122945T1 (en:Method)
DK (2) DK3186244T3 (en:Method)
EA (2) EA033300B1 (en:Method)
ES (2) ES2796089T3 (en:Method)
HR (1) HRP20201023T1 (en:Method)
HU (2) HUE059640T2 (en:Method)
IL (2) IL250344B (en:Method)
MX (1) MX369649B (en:Method)
MY (2) MY188089A (en:Method)
NZ (2) NZ729118A (en:Method)
PH (2) PH12017500184B1 (en:Method)
PL (2) PL3572410T3 (en:Method)
PT (2) PT3572410T (en:Method)
SG (3) SG10201911558UA (en:Method)
WO (1) WO2016030335A1 (en:Method)
ZA (1) ZA201802864B (en:Method)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016030335A1 (en) 2014-08-25 2016-03-03 Medivir Ab Dioxolane analogues of uridine for the treatment of cancer
CN106543220A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
SG11201804774YA (en) * 2015-12-11 2018-07-30 NuCana plc Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
SG11201806855WA (en) 2016-03-02 2018-09-27 Medivir Ab Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
CN106432328B (zh) * 2016-09-14 2019-03-22 江苏福瑞生物医药有限公司 一种索非布韦中间体的制备方法
US20190276481A1 (en) * 2016-11-18 2019-09-12 Neurovive Pharmaceutical Ab Liver Prodrugs of Mitochondrial Proton Ionophores
GB201709471D0 (en) * 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
JP7337539B2 (ja) * 2018-06-21 2023-09-04 メディヴィル・アクチエボラーグ 白血病療法のための塩基修飾シチジンヌクレオチド
WO2019245444A1 (en) 2018-06-21 2019-12-26 Medivir Ab Base-modified cytidine nucleotides for leukemia therapy
RS65316B1 (sr) * 2019-02-18 2024-04-30 Medivir Ab Kombinacija lekova za upotrebu u postupku lečenja raka jetre
CN110964057B (zh) * 2019-12-25 2022-05-06 东南大学 一种利用微流体反应装置制备索非布韦中间体的方法
CN113402546A (zh) * 2020-03-17 2021-09-17 浙江四维医药科技有限公司 一种瑞德西韦磷酸中间体尾链动态动力学拆分方法
CN115485029A (zh) * 2020-04-15 2022-12-16 美迪维尔公司 用于肝癌的miv-818/乐伐替尼组合疗法
CN113754692B (zh) * 2020-06-03 2022-06-10 上海交通大学 瑞德西韦中间体(s,s)-氨基磷酸酯的不对称催化合成方法
CN114685558A (zh) * 2020-12-28 2022-07-01 尚科生物医药（上海）有限公司 一种瑞德西韦中间体的制备方法
CN114249764A (zh) * 2021-11-10 2022-03-29 宁波大学 一种磷酰胺酯类前药的中间体及其制备方法与应用
WO2025155547A1 (en) * 2024-01-17 2025-07-24 University Of Georgia Research Foundation, Inc. An efficient synthesis of beta-l-5-[(e)-2-bromovinyl)-1-((2s,4s)-2-(hydroxymethyl)-1,3-(dioxolane-4-yl) uracil)] (l-bhdu) via chiral pure l-dioxolane

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
CN100376570C (zh) * 2000-10-13 2008-03-26 希拉生物化学股份有限公司 改善胞间传输的二氧戊环类似物
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
WO2007106450A2 (en) * 2006-03-10 2007-09-20 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase in combination therapy
KR20090057050A (ko) * 2006-09-01 2009-06-03 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 암치료를 위한 트록사시타빈 전구약물
PL216525B1 (pl) * 2006-10-17 2014-04-30 Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk 5'-O-[(N-acylo)amidoditiofosforano] nukleozydy oraz sposób wytwarzania 5'-O-[(N-acylo)amidofosforano]-,5'-O-[(N-acylo)amidotiofosforano]-, 5'-O-[(N-acylo)amidoditiofosforano]nukleozydów
US20130143835A1 (en) * 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
CN105934438A (zh) * 2013-11-27 2016-09-07 艾登尼克斯药业有限公司 用于治疗肝癌的核苷酸
WO2016030335A1 (en) * 2014-08-25 2016-03-03 Medivir Ab Dioxolane analogues of uridine for the treatment of cancer

Also Published As

Publication number Publication date
HRP20201023T1 (hr) 2020-10-16
HUE050705T2 (hu) 2020-12-28
WO2016030335A1 (en) 2016-03-03
US20190389890A1 (en) 2019-12-26
DK3186244T3 (da) 2020-07-13
KR102398714B1 (ko) 2022-05-17
CN107074826B (zh) 2020-05-22
US20170267705A1 (en) 2017-09-21
EA033300B1 (ru) 2019-09-30
MX2017002328A (es) 2017-05-22
CN110790789A (zh) 2020-02-14
CN110804072B (zh) 2023-05-12
US20230117570A1 (en) 2023-04-20
JP6663424B2 (ja) 2020-03-11
US20190100541A1 (en) 2019-04-04
MY188089A (en) 2021-11-17
NZ729118A (en) 2022-02-25
BR112017003898B1 (pt) 2022-10-18
CY1122945T1 (el) 2021-10-29
KR20200035482A (ko) 2020-04-03
US20210054008A1 (en) 2021-02-25
SG10202001117YA (en) 2020-04-29
DK3572410T3 (da) 2022-08-29
US10144750B2 (en) 2018-12-04
US10336780B2 (en) 2019-07-02
CA3128645A1 (en) 2016-03-03
EA201890648A2 (ru) 2018-08-31
US20200239502A1 (en) 2020-07-30
EA201890648A3 (ru) 2019-02-28
EA201790328A1 (ru) 2017-08-31
SG11201701172SA (en) 2017-03-30
AU2018201980B2 (en) 2019-05-16
CN110790789B (zh) 2023-05-12
EP3572410B1 (en) 2022-07-20
JP2020090535A (ja) 2020-06-11
US10654877B2 (en) 2020-05-19
IL250344A0 (en) 2017-03-30
CN107074826A (zh) 2017-08-18
KR20170046736A (ko) 2017-05-02
AU2015308988B2 (en) 2018-04-26
PH12019501919A1 (en) 2020-09-14
MY198325A (en) 2023-08-24
EP3572410A1 (en) 2019-11-27
CN111269264A (zh) 2020-06-12
EP3186244A1 (en) 2017-07-05
US11447511B2 (en) 2022-09-20
HUE059640T2 (hu) 2022-12-28
CN110804072A (zh) 2020-02-18
ES2796089T3 (es) 2020-11-25
PL3186244T3 (pl) 2020-11-16
AU2015308988C1 (en) 2018-09-06
CA2956251C (en) 2022-10-25
BR112017003898A2 (pt) 2017-12-05
CA2956251A1 (en) 2016-03-03
AU2018201980A1 (en) 2018-04-12
ZA201802864B (en) 2019-07-31
IL266766A (en) 2019-07-31
AU2015308988A1 (en) 2017-02-23
EA031106B1 (ru) 2018-11-30
JP6905609B2 (ja) 2021-07-21
IL266766B (en) 2020-05-31
ES2927212T3 (es) 2022-11-03
US20230382931A1 (en) 2023-11-30
IL250344B (en) 2020-01-30
JP2017526677A (ja) 2017-09-14
US10822360B2 (en) 2020-11-03
PH12017500184A1 (en) 2017-06-28
PL3572410T3 (pl) 2022-10-03
EP3186244B1 (en) 2020-04-22
CA3128645C (en) 2023-06-27
NZ762628A (en) 2023-04-28
KR102396905B1 (ko) 2022-05-13
PH12017500184B1 (en) 2017-06-28
PT3572410T (pt) 2022-09-15
PT3186244T (pt) 2020-05-29
SG10201911558UA (en) 2020-01-30

Similar Documents

Publication Publication Date Title
MX369649B (es) Analogos de dioxolano de uridina para el tratamiento del cancer.
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
EA201791563A1 (ru) Замещенные нуклеозидные производные, полезные в качестве агентов против рака
EA201691857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201891251A1 (ru) Бициклические ингибиторы pad4
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
PH12018502497A1 (en) Adenosine derivatives for use in the treatment of cancer
MX389724B (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
EA201690523A1 (ru) Триазолопиридины, композиции и способы их применения
UY37466A (es) N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
EA201791249A1 (ru) Получаемые из cd44v6 циклические пептиды для лечения злокачественных опухолей и связанных с ангиогенезом заболеваний
UA117779C2 (uk) Піразини як модулятори gpr6
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
MX388409B (es) Composiciones y metodos para tratar canceres.
MX2019001979A (es) Agonista de ppar? para el tratamiento de neoplasias hematicas.
MX2019002017A (es) Derivados de sofosbuvir para el tratamiento de la hepatitis c.
WO2019040104A3 (en) COMPOUNDS, RELATED SALTS AND METHODS OF TREATING DISEASES
PH12017500492A1 (en) Crystalline bace inhibitors
PH12017501063A1 (en) Compounds for the treatment of cancer

Legal Events

Date Code Title Description
FG Grant or registration